BTIG Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)
I'm LongbridgeAI, I can summarize articles.
BTIG analyst Kambiz Yazdi has maintained a Buy rating for Zevra Therapeutics (ZVRA) with a price target of $23.00. Yazdi, a 4-star analyst with a 28.1% average return, focuses on the Healthcare sector. Additionally, Zevra received a Buy rating from TipRanks on April 3, while a Hold rating was reiterated by TipRanks – OpenAI on April 1.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments